Phase 2 N=7 A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations
Lymphangioma
Primary: Change in Volume of Lymphatic Malformation — 3.7; -4.3; -1.0; -31.7 percentage of volume change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 First-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease
Coronary Artery Disease
Primary: Angiographic In-Stent Late Lumen Loss — 0.09 mm
Phase 2 N=43 Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
Glioma
Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants
Phase 2 N=18 Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
T Cell Lymphoma
Primary: The Primary Efficacy Endpoint for This Study is Overall Regressive Response Rate (ORRR): Proportion of Patients With a Best Response of Complete Response (CR), Partial…
Phase 2 N=100 A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety
Rheumatoid Arthritis
Primary: Serum Concentrations of Adalimumab at Weeks 12 and 24 — 5.72; 6.23; 5.95; 6.17 µg/mL
Phase 2 N=296 Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
Asthma
Primary: Trough FEV1 Response After 4 Weeks — 0.004; 0.083; 0.090; 0.080 Liter — p=0.0754
Phase 2 N=9 Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Relapse-free Complete Clinical Response — 54 Months
Phase 2 N=5 Sirolimus Injections for Autoimmune Scleritis
Scleritis
Primary: Number of Participants Who Experience at Least 2-step Reduction or Reduction to Grade 0 of Scleral Inflammation in the Study Eye According to the National Eye Institute…
Phase 2 N=328 Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD
Pulmonary Disease, Chronic Obstructive
Primary: Trough FEV1 Response at Week 4 — -0.032; 0.059; 0.100; 0.100 Liter — p=<0.0001
Phase 2 N=20 Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study
Retinopathy of Prematurity
Primary: Regression of Retinopathy of Prematurity (ROP) in Premature Infants by Propranolol Therapy — 4; 8 cases
Phase 2 N=96 Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs
Tuberculosis · AIDS-related Complex
Primary: Sputum Conversion — 36; 60; 36 percentage of participants
Phase 2 N=56 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
Recurrent Uterine Sarcoma · Stage III Uterine Sarcoma · Stage IV Uterine Sarcoma
Primary: Objective Overall Response Rate — 2; 0 participants
Phase 2 N=62 Transcranial Direct Current Stimulation in Patients With Disorders of Consciousness
Vegetative State · Minimally Conscious State · Disorders of Consciousness
Primary: Change in CRS-R Total Scores — 12.17; 10.60 units on a scale
Phase 2 N=10 Ketamine Infusion for Obsessive-Compulsive Disorder
Obsessive-compulsive Disorder
Primary: OCD Severity — -2.7 units on a scale
Phase 2 N=60 CINJALL: Treatment for Children With Acute Lymphocytic Leukemia
Acute Lymphocytic Leukemia
Primary: Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years — 64.9 percentage of participants